Tiazac appeals court ruling
Miami federal court ruling in favor of Andrx upheld on appeal. The court ruled that Andrx' generic version of Biovail/Forest's Tiazac (diltiazem) does not infringe Biovail's patent No. 5,529,791. Biovail listed a patent (No. 6,162,463) in January, triggering new litigation (1"The Pink Sheet" Feb. 5, p. 27)
You may also be interested in...
Forest may be able to forestall generic competition to Tiazac until mid-2003 as a result of a recently listed patent on the once-daily diltiazem product.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials